37
Participants
Start Date
May 31, 2006
Primary Completion Date
September 30, 2011
Study Completion Date
September 30, 2011
azacitidine
Azacitidine subcutaneously once daily on days 1-5 or days 1-5 and 8-12. Treatment repeats every 28 days for up to 7 courses in the absence of relapse (after achieving complete or partial remission), disease progression, or unacceptable toxicity.
lenalidomide
Oral lenalidomide once daily on days 1-14 or days 1-21.Treatment repeats every 28 days for up to 7 courses in the absence of relapse (after achieving complete or partial remission), disease progression, or unacceptable toxicity.
Cleveland Clinic Taussig Cancer Instititute, Case Comprehensive Cancer Center, Cleveland
University of California at Los Angeles, Los Angeles
H. Lee Moffitt Cancer Center and Research Institute at University of South Florida, Tampa
National Cancer Institute (NCI)
NIH
Mikkael Sekeres MD
OTHER